Literature DB >> 7719413

Expression rate of cytokine mRNA in the liver of chronic hepatitis C: comparison with chronic hepatitis B.

R Fukuda1, S Satoh, X T Nguyen, Y Uchida, N Kohge, S Akagi, S Ikeda, M Watanabe, S Fukumoto.   

Abstract

This study was carried out to test the hypothesis that, in chronic hepatitis (CH), inflammatory processes, including viral replication, host immune response, and hepatocyte destruction, are regulated by a cytokine network in the liver. Expression of the mRNA of the cytokines IL1-beta, IL2, IL4, IL5, IL6, TNF-alpha, and IFN-gamma, the lymphocyte markers CD4 and CD8, and the HLA class I molecule, beta 2-microglobulin (B2MG) in the liver tissue of 20 CH(C) cases and 9 CH(B) patients was investigated by the reverse transcription polymerase chain reaction (RT-PCR) method. TNF-alpha, CD4, and B2MG mRNA were detected in 100% of cases of in both CH(B) and CH(C). The expression rates of IL1-beta, IL2, IL4, IFN-gamma, and CD8 mRNA were 80%, 40%, 25%, 40%, and 80% in CH(C) and 88.9%, 44.5%, 30%, 55.6%, and 100% in CH(B). IL6 mRNA was detected only in CH(B), in 22.2% of cases, IL5 mRNA was not detected in either CH(B) or CH(C). IL2, IL4, and IFN-gamma mRNA were expressed significantly more frequently in patients who had high serum ALT and a high histological activity index (HAI) score. There was no difference in cytokine expression between CH(B) and CH(C), except in IL6, suggesting the existence of a common immunopathogenesis for CH(B) and CH(C). In chronic viral hepatitis, IL1-beta and TNF-alpha appear to play a major role in immune responses and IL2, IL4, and IFN-gamma seem to be associated with increased cytotoxic T cell response.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7719413     DOI: 10.1007/bf01211373

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  34 in total

1.  Monokine gene expression in normal human liver: selective involvement of the portal compartment.

Authors:  D Emilie; E Navratil; O Devergne; M Reynes; M C Crevon; D Samuel; P Galanaud
Journal:  Liver       Date:  1992-02

2.  In-vitro cell-mediated cytotoxicity for autologous liver cells in chronic non-A, non-B hepatitis.

Authors:  M Mondelli; A Alberti; F Tremolada; R Williams; A L Eddleston; G Realdi
Journal:  Clin Exp Immunol       Date:  1986-01       Impact factor: 4.330

3.  Elevated plasma interleukin-6 and increased severity and mortality in alcoholic hepatitis.

Authors:  N Sheron; G Bird; J Goka; G Alexander; R Williams
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

4.  HLA B44-restricted cytotoxic T lymphocytes recognizing an epitope on hepatitis C virus nucleocapsid protein.

Authors:  H Kita; T Moriyama; T Kaneko; I Harase; M Nomura; H Miura; I Nakamura; Y Yazaki; M Imawari
Journal:  Hepatology       Date:  1993-11       Impact factor: 17.425

5.  Interleukin-2 activity in chronic active liver diseases: response by T cells and in the autologous mixed lymphocyte reaction.

Authors:  K Yoshioka; S Kakumu; H Murakami; K Fukui
Journal:  Clin Exp Immunol       Date:  1984-06       Impact factor: 4.330

6.  A sequential study of viral DNA in serum in experimental transmission of duck hepatitis B virus.

Authors:  R Fukuda; S Fukumoto; Y Shimada
Journal:  J Med Virol       Date:  1987-04       Impact factor: 2.327

7.  Cytotoxic T cell recognition of Epstein-Barr virus-infected B cells. II. Blocking studies with monoclonal antibodies to HLA determinants.

Authors:  L E Wallace; D J Moss; A B Rickinson; A J McMichael; M A Epstein
Journal:  Eur J Immunol       Date:  1981-09       Impact factor: 5.532

8.  Interleukin-6 production by peripheral blood monocytes in patients with chronic liver disease and acute viral hepatitis.

Authors:  C Müller; C C Zielinski
Journal:  J Hepatol       Date:  1992-07       Impact factor: 25.083

9.  Serial observation of lymphocyte subpopulations and interleukin 2 production of T cells from patients with acute viral hepatitis and chronic active hepatitis.

Authors:  M Onji; H Kondo; Y Ohta
Journal:  Hepatogastroenterology       Date:  1988-02

10.  Monoclonal antibody directed against interleukin 2. I. Inhibition of T lymphocyte mitogenesis and the in vitro differentiation of alloreactive cytolytic T cells.

Authors:  S Gillis; A E Gillis; C S Henney
Journal:  J Exp Med       Date:  1981-09-01       Impact factor: 14.307

View more
  5 in total

1.  Growth factor mRNA expression in normal colorectal mucosa and in uninvolved mucosa from ulcerative colitis patients.

Authors:  A Chowdhury; R Fukuda; S Fukumoto
Journal:  J Gastroenterol       Date:  1996-06       Impact factor: 7.527

2.  Expression of interferon-alpha receptor mRNA in the liver in chronic liver diseases associated with hepatitis C virus: relation to effectiveness of interferon therapy.

Authors:  R Fukuda; N Ishimura; S Ishihara; A Tokuda; S Satoh; S Sakai; S Akagi; M Watanabe; S Fukumoto
Journal:  J Gastroenterol       Date:  1996-12       Impact factor: 7.527

3.  Cytokine gene expression in the gastric mucosa: its role in chronic gastritis.

Authors:  S Ishihara; R Fukuda; S Fukumoto
Journal:  J Gastroenterol       Date:  1996-08       Impact factor: 7.527

4.  The hepatitis B virus X protein activates nuclear factor of activated T cells (NF-AT) by a cyclosporin A-sensitive pathway.

Authors:  E Lara-Pezzi; A L Armesilla; P L Majano; J M Redondo; M López-Cabrera
Journal:  EMBO J       Date:  1998-12-01       Impact factor: 11.598

5.  The expression of IL-2, IL-4 and interferon-gamma (IFN-gamma) mRNA using liver biopsies at different phases of acute exacerbation of chronic hepatitis B.

Authors:  R Fukuda; N Ishimura; T X Nguyen; A Chowdhury; S Ishihara; N Kohge; S Akagi; M Watanabe; S Fukumoto
Journal:  Clin Exp Immunol       Date:  1995-06       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.